Lyrica (pregabalin) does not show up on standard drug tests. The five-panel and ten-panel screens used by most employers and federal agencies are not designed to detect it. However, pregabalin can be identified through specialized testing when a lab specifically looks for it, and it has been shown to trigger false positive results for benzodiazepines on certain screening methods.
Why Standard Drug Tests Miss Lyrica
Standard workplace and federal drug tests screen for a specific set of substances: marijuana, cocaine, opiates, amphetamines, and PCP. Pregabalin falls outside all of these categories. It is not an opioid, not a benzodiazepine, and not structurally related to any of the five drug classes on a standard panel. If you take Lyrica and are given a routine urine drug screen, the test will not flag pregabalin as a positive result for any of those substances.
The Department of Transportation confirms that DOT-mandated testing covers only those five drug classes. That said, employers are allowed to run additional “company authority” testing programs beyond the DOT panel, and some do choose to add pregabalin or gabapentin to their screening panels, particularly in industries or regions where misuse of these medications has become more common.
False Positives for Benzodiazepines
Here is where things get tricky. While Lyrica won’t register as itself on a standard screen, it can cause a false positive for benzodiazepines when the test uses an immunoassay method, which is the most common initial screening technique. A retrospective study examining urine samples that initially tested positive for benzodiazepines found that when those samples were sent for confirmatory analysis, pregabalin was the actual substance detected in 5 out of 12 cases. Gabapentin, a closely related drug, accounted for 2 more.
This means if you take Lyrica and undergo a standard immunoassay screen, there is a real possibility the test flags you as positive for benzodiazepines like Valium or Xanax, even though you have not taken any. If this happens, the sample should be sent for confirmatory testing using more precise methods (chromatography paired with mass spectrometry), which can distinguish pregabalin from actual benzodiazepines and clear the false positive.
When Labs Test for Pregabalin Directly
Some testing programs do specifically order a pregabalin test. Pain management clinics, addiction treatment programs, and certain employers may request this as an add-on. Quest Diagnostics, for example, offers a dedicated pregabalin test that uses chromatography and mass spectrometry to confirm its presence with high accuracy. This type of test is not guessing based on chemical similarity. It identifies the exact molecule.
In urine, pregabalin is typically detectable for 1 to 3 days after your last dose. Hair testing extends that window significantly, potentially capturing months of use depending on the length of hair collected. Blood and saliva detection windows are shorter, though precise timelines for pregabalin in those samples are less well established in published research.
What Happens If You Have a Prescription
If pregabalin does show up on a test, whether through a targeted panel or a false positive that triggers further analysis, having a valid prescription changes the outcome. In regulated testing programs, a Medical Review Officer reviews any positive result before it is reported to an employer. The MRO’s job is to determine whether there is a legitimate medical explanation.
This process involves more than just your word. The MRO will call the pharmacy to verify the prescription is authentic, and may contact your prescribing doctor if questions remain. Simply showing a photo of your pill bottle label is not considered sufficient verification. If your prescription checks out, the result is reported as negative. If you are taking Lyrica as prescribed and know a drug test is coming, having your pharmacy information readily available can speed up this process.
Lyrica’s Changing Legal Status
Part of the reason pregabalin is appearing on more specialized panels is its reclassification. Lyrica is a Schedule V controlled substance at the federal level, the lowest scheduling category, reflecting its recognized potential for misuse. Several states and other countries have moved to tighten restrictions further in recent years due to rising rates of pregabalin misuse, particularly in combination with opioids. As scrutiny increases, so does the likelihood that testing programs will add it to their panels. If you are in a pain management program, probation, or a substance use treatment program, there is a good chance pregabalin is already on the list of drugs being monitored.